View in EDS HTML Full Text PDF Full Text

Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort.

Saved in:
Bibliographic Details
Title: Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort.
Authors: Saeed A; Department of Medicine, Division of Hematology & Oncology, University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA, USA. saeeda3@upmc.edu.; UPMC Hillman Cancer Center, Pittsburgh, PA, USA. saeeda3@upmc.edu., Park R; Division of Hematology and Medical Oncology, Moffitt Cancer Cente, Tampa, FL, USA., Pathak H; Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USA., Al-Bzour AN; Department of Medicine, Division of Hematology & Oncology, University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA, USA., Dai J; Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS, USA., Phadnis M; Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS, USA., Al-Rajabi R; Department of Medicine, Division of Medical Oncology, University of Kansas Medical Center, Kansas City, Ks, USA.; University of Kansas Cancer Center, Kansas City, KS, USA., Kasi A; Department of Medicine, Division of Medical Oncology, University of Kansas Medical Center, Kansas City, Ks, USA.; University of Kansas Cancer Center, Kansas City, KS, USA., Baranda J; Department of Medicine, Division of Medical Oncology, University of Kansas Medical Center, Kansas City, Ks, USA.; University of Kansas Cancer Center, Kansas City, KS, USA., Sun W; Department of Medicine, Division of Medical Oncology, University of Kansas Medical Center, Kansas City, Ks, USA.; University of Kansas Cancer Center, Kansas City, KS, USA., Williamson S; Department of Medicine, Division of Medical Oncology, University of Kansas Medical Center, Kansas City, Ks, USA.; University of Kansas Cancer Center, Kansas City, KS, USA., Chiu YC; UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Osmanbeyoglu HU; UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Madan R; Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USA., Abushukair H; Department of Medicine, Division of Hematology & Oncology, University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA, USA., Mulvaney K; University of Kansas Cancer Center, Kansas City, KS, USA., Godwin AK; Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USA.; University of Kansas Cancer Center, Kansas City, KS, USA.; Kansas Institute for Precision Medicine, University of Kansas Medical Center, Kansas City, KS, USA., Saeed A; Department of Pathology and Laboratory Medicine, University of Vermont Medical Center, Burlington, VT, USA.
Source: Nature communications [Nat Commun] 2024 Feb 20; Vol. 15 (1), pp. 1533. Date of Electronic Publication: 2024 Feb 20.
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 38378868
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Saeed+A%22">Saeed A</searchLink>; Department of Medicine, Division of Hematology & Oncology, University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA, USA. saeeda3@upmc.edu.; UPMC Hillman Cancer Center, Pittsburgh, PA, USA. saeeda3@upmc.edu.<br /><searchLink fieldCode="AU" term="%22Park+R%22">Park R</searchLink>; Division of Hematology and Medical Oncology, Moffitt Cancer Cente, Tampa, FL, USA.<br /><searchLink fieldCode="AU" term="%22Pathak+H%22">Pathak H</searchLink>; Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USA.<br /><searchLink fieldCode="AU" term="%22Al-Bzour+AN%22">Al-Bzour AN</searchLink>; Department of Medicine, Division of Hematology & Oncology, University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA, USA.<br /><searchLink fieldCode="AU" term="%22Dai+J%22">Dai J</searchLink>; Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS, USA.<br /><searchLink fieldCode="AU" term="%22Phadnis+M%22">Phadnis M</searchLink>; Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS, USA.<br /><searchLink fieldCode="AU" term="%22Al-Rajabi+R%22">Al-Rajabi R</searchLink>; Department of Medicine, Division of Medical Oncology, University of Kansas Medical Center, Kansas City, Ks, USA.; University of Kansas Cancer Center, Kansas City, KS, USA.<br /><searchLink fieldCode="AU" term="%22Kasi+A%22">Kasi A</searchLink>; Department of Medicine, Division of Medical Oncology, University of Kansas Medical Center, Kansas City, Ks, USA.; University of Kansas Cancer Center, Kansas City, KS, USA.<br /><searchLink fieldCode="AU" term="%22Baranda+J%22">Baranda J</searchLink>; Department of Medicine, Division of Medical Oncology, University of Kansas Medical Center, Kansas City, Ks, USA.; University of Kansas Cancer Center, Kansas City, KS, USA.<br /><searchLink fieldCode="AU" term="%22Sun+W%22">Sun W</searchLink>; Department of Medicine, Division of Medical Oncology, University of Kansas Medical Center, Kansas City, Ks, USA.; University of Kansas Cancer Center, Kansas City, KS, USA.<br /><searchLink fieldCode="AU" term="%22Williamson+S%22">Williamson S</searchLink>; Department of Medicine, Division of Medical Oncology, University of Kansas Medical Center, Kansas City, Ks, USA.; University of Kansas Cancer Center, Kansas City, KS, USA.<br /><searchLink fieldCode="AU" term="%22Chiu+YC%22">Chiu YC</searchLink>; UPMC Hillman Cancer Center, Pittsburgh, PA, USA.<br /><searchLink fieldCode="AU" term="%22Osmanbeyoglu+HU%22">Osmanbeyoglu HU</searchLink>; UPMC Hillman Cancer Center, Pittsburgh, PA, USA.<br /><searchLink fieldCode="AU" term="%22Madan+R%22">Madan R</searchLink>; Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USA.<br /><searchLink fieldCode="AU" term="%22Abushukair+H%22">Abushukair H</searchLink>; Department of Medicine, Division of Hematology & Oncology, University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA, USA.<br /><searchLink fieldCode="AU" term="%22Mulvaney+K%22">Mulvaney K</searchLink>; University of Kansas Cancer Center, Kansas City, KS, USA.<br /><searchLink fieldCode="AU" term="%22Godwin+AK%22">Godwin AK</searchLink>; Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USA.; University of Kansas Cancer Center, Kansas City, KS, USA.; Kansas Institute for Precision Medicine, University of Kansas Medical Center, Kansas City, KS, USA.<br /><searchLink fieldCode="AU" term="%22Saeed+A%22">Saeed A</searchLink>; Department of Pathology and Laboratory Medicine, University of Vermont Medical Center, Burlington, VT, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101528555%22">Nature communications</searchLink> [Nat Commun] 2024 Feb 20; Vol. 15 (1), pp. 1533. <i>Date of Electronic Publication: </i>2024 Feb 20.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Pub%2E+Group%22">Nature Pub. Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101528555 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2041-1723 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220411723%22">20411723 </searchLink><i>NLM ISO Abbreviation: </i>Nat Commun <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38378868
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41467-024-45960-2
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1533
    Titles:
      – TitleFull: Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Saeed A
      – PersonEntity:
          Name:
            NameFull: Park R
      – PersonEntity:
          Name:
            NameFull: Pathak H
      – PersonEntity:
          Name:
            NameFull: Al-Bzour AN
      – PersonEntity:
          Name:
            NameFull: Dai J
      – PersonEntity:
          Name:
            NameFull: Phadnis M
      – PersonEntity:
          Name:
            NameFull: Al-Rajabi R
      – PersonEntity:
          Name:
            NameFull: Kasi A
      – PersonEntity:
          Name:
            NameFull: Baranda J
      – PersonEntity:
          Name:
            NameFull: Sun W
      – PersonEntity:
          Name:
            NameFull: Williamson S
      – PersonEntity:
          Name:
            NameFull: Chiu YC
      – PersonEntity:
          Name:
            NameFull: Osmanbeyoglu HU
      – PersonEntity:
          Name:
            NameFull: Madan R
      – PersonEntity:
          Name:
            NameFull: Abushukair H
      – PersonEntity:
          Name:
            NameFull: Mulvaney K
      – PersonEntity:
          Name:
            NameFull: Godwin AK
      – PersonEntity:
          Name:
            NameFull: Saeed A
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 20
              M: 02
              Text: 2024 Feb 20
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 2041-1723
          Numbering:
            – Type: volume
              Value: 15
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Nature communications
              Type: main
ResultId 1